US Patent

US10772897 — Method for on-demand contraception

Method of Use · Assigned to Laboratoire HRA Pharma SAS · Expires 2030-04-13 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for on-demand contraception that involves administering ulipristal acetate within 72 hours before or 120 hours after intercourse.

USPTO Abstract

The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.

Drugs covered by this patent

ulipristal-acetate (ULIPRISTAL ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2958`	—	ulipristal-acetate

Patent Metadata

Patent number: US10772897
Jurisdiction: US
Classification: Method of Use
Expires: 2030-04-13
Drug substance claim: No
Drug product claim: No
Assignee: Laboratoire HRA Pharma SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.